These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18000367)

  • 1. Disruption of the FA/BRCA pathway in bladder cancer.
    Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
    Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
    Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
    Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
    Gallmeier E; Calhoun ES; Rago C; Brody JR; Cunningham SC; Hucl T; Gorospe M; Kohli M; Lengauer C; Kern SE
    Gastroenterology; 2006 Jun; 130(7):2145-54. PubMed ID: 16762635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
    Kachnic LA; Li L; Fournier L; Willers H
    Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
    Marsit CJ; Liu M; Nelson HH; Posner M; Suzuki M; Kelsey KT
    Oncogene; 2004 Jan; 23(4):1000-4. PubMed ID: 14647419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
    Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
    Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells.
    Xie Y; de Winter JP; Waisfisz Q; Nieuwint AW; Scheper RJ; Arwert F; Hoatlin ME; Ossenkoppele GJ; Schuurhuis GJ; Joenje H
    Br J Haematol; 2000 Dec; 111(4):1057-64. PubMed ID: 11167740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
    Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
    Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
    Levran O; Attwooll C; Henry RT; Milton KL; Neveling K; Rio P; Batish SD; Kalb R; Velleuer E; Barral S; Ott J; Petrini J; Schindler D; Hanenberg H; Auerbach AD
    Nat Genet; 2005 Sep; 37(9):931-3. PubMed ID: 16116424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.
    Ferrer M; de Winter JP; Mastenbroek DC; Curiel DT; Gerritsen WR; Giaccone G; Kruyt FA
    Cancer Gene Ther; 2004 Aug; 11(8):539-46. PubMed ID: 15192709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
    Wreesmann VB; Estilo C; Eisele DW; Singh B; Wang SJ
    ORL J Otorhinolaryngol Relat Spec; 2007; 69(4):218-25. PubMed ID: 17409780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
    Snyder ER; Ricker JL; Chen Z; Waes CV
    Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.
    Wilson JB; Yamamoto K; Marriott AS; Hussain S; Sung P; Hoatlin ME; Mathew CG; Takata M; Thompson LH; Kupfer GM; Jones NJ
    Oncogene; 2008 Jun; 27(26):3641-52. PubMed ID: 18212739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.
    Gallmeier E; Hucl T; Calhoun ES; Cunningham SC; Bunz F; Brody JR; Kern SE
    Cancer Biol Ther; 2007 May; 6(5):654-60. PubMed ID: 17387268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four human FANCG polymorphic variants show normal biological function in hamster CHO cells.
    Hinz JM; Nham PB; Yamada NA; Tebbs RS; Salazar EP; Hinz AK; Mohrenweiser HW; Jones IM; Thompson LH
    Mutat Res; 2006 Dec; 602(1-2):34-42. PubMed ID: 17010390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2.
    Hussain S; Wilson JB; Blom E; Thompson LH; Sung P; Gordon SM; Kupfer GM; Joenje H; Mathew CG; Jones NJ
    DNA Repair (Amst); 2006 May; 5(5):629-40. PubMed ID: 16621732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.
    Palagyi A; Neveling K; Plinninger U; Ziesch A; Targosz BS; Denk GU; Ochs S; Rizzani A; Meier D; Thasler WE; Hanenberg H; De Toni EN; Bassermann F; Schäfer C; Göke B; Schindler D; Gallmeier E
    Mol Cancer; 2010 May; 9():127. PubMed ID: 20509860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia.
    Hess CJ; Ameziane N; Schuurhuis GJ; Errami A; Denkers F; Kaspers GJ; Cloos J; Joenje H; Reinhardt D; Ossenkoppele GJ; Zwaan CM; Waisfisz Q
    Cell Oncol; 2008; 30(4):299-306. PubMed ID: 18607065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.
    Kim WJ; Kim EJ; Jeong P; Quan C; Kim J; Li QL; Yang JO; Ito Y; Bae SC
    Cancer Res; 2005 Oct; 65(20):9347-54. PubMed ID: 16230397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic subtyping of Fanconi anemia by comprehensive mutation screening.
    Ameziane N; Errami A; Léveillé F; Fontaine C; de Vries Y; van Spaendonk RM; de Winter JP; Pals G; Joenje H
    Hum Mutat; 2008 Jan; 29(1):159-66. PubMed ID: 17924555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.